ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production

ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production

Abstract Introduction EGFR mutations in non-small cell lung cancer (NSCLC) are associated with a poor response to immune checkpoint inhibitors (ICIs), and only 20% of NSCLC patients harboring EGFR mutations benefit from immunotherapy. Novel biomarkers or therapeutics are needed to predict NSCLC prog...

Full description

Bibliographic Details
Main Authors: Dantong Sun, Haili Qian, Jinsong Wang, Tongji Xie, Fei Teng, Junling Li, Puyuan Xing
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Cell Communication and Signaling
Subjects:
EGFR-mutant lung adenocarcinoma
ARID1A
Immunotherapy
Autophagy
Type I interferon
Online Access:https://doi.org/10.1186/s12964-022-00958-5

Internet

https://doi.org/10.1186/s12964-022-00958-5

Similar Items